



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/024,298	12/21/2001	Akio Matsuda	1254-0191P	3320
2292	7590	07/01/2004	EXAMINER	
BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747			MCKELVEY, TERRY ALAN	
			ART UNIT	PAPER NUMBER
			1636	
DATE MAILED: 07/01/2004				

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/024,298

Applicant(s)

MATSUDA ET AL.

Examiner

Terry A. McKelvey

Art Unit

1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-31 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-31 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_.

Art Unit: 1636

**DETAILED ACTION**

***Election/Restrictions***

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-2, 7, and 10, drawn to protein and membrane plus protein, classified in class 530, subclass 350.
- II. Claims 3-6 and 8-9, drawn to polynucleotide, vector, and cell, classified in class 536, subclass 23.1 and class 435, subclasses 320.1, 325, 243, and 419.
- III. Claim 11, drawn to process for producing a protein, classified in class 435, subclass 69.1.
- IV. Claim 12, drawn to process for diagnosing a disease, classified in class 435, subclass 6.
- V. Claims 13-15, drawn to method for screening compounds and kit, classified in class 435, subclass 29.
- VI. Claims 16, 24, and 26, drawn to antibody and pharmaceutical composition, classified in class 530, subclass 387.1 and class 514, subclass 2.
- VII. Claim 17, drawn to process for producing an antibody, classified in class 424, subclass 184.1.
- VIII. Claims 18, and 25-26, drawn to antisense oligonucleotide and pharmaceutical composition,

Art Unit: 1636

classified in class 536, subclass 24.5 and class 514, subclass 44.

- IX. Claim 19, drawn to ribozyme, classified in class 536, subclass 24.5.
- X. Claim 20, only as drawn to method for treating disease comprising administering a compound, classified in class 514, subclass 1.
- XI. Claim 20, only as drawn to method for treating disease comprising administering an antibody, classified in class 514, subclass 2.
- XII. Claim 20, only as drawn to method for treating disease comprising administering an antisense oligonucleotide, classified in class 514, subclass 44.
- XIII. Claim 20, only as drawn to method for treating disease comprising administering a ribozyme, classified in class 514, subclass 44.
- XIV. Claims 21-23, drawn to pharmaceutical composition and method of treating disease, classified in class 514, subclass 1.
- XV. Claim 27, drawn to method for obtaining a novel gene, classified in class 435, subclass 6.
- XVI. Claim 28, drawn to computer readable medium having sequence data, classified in class 712, subclass 300.

Art Unit: 1636

XVII.Claim 29, drawn to method for calculating identity,  
classified in class 341, subclass 899.

XVIII.Claim 30, drawn to substrate comprising  
polynucleotides, classified in class 536, subclass  
23.1.

XIX. Claim 31, drawn to substrate comprising amino acid  
sequences, classified in class 530, subclass 350.

Groups I, II, etc are comprised of multiple inventions  
which are the products or methods drawn to different, distinct,  
and/or independent sequences which do not render obvious each  
other and thus are patentably distinct. If any of Groups I, II,  
etc (any group drawn to more than one sequence) are elected,  
applicants must elect a single invention which is the product or  
method drawn to one specific sequence to which the claims will  
be restricted. Note, this restriction to examination of a  
single sequence is due to the now very high and undue burden for  
examining more than one sequence which is caused by the  
continued exponential increase of size of the sequence databases  
to be searched for each sequence, resulting in a corresponding  
increase in computer search time and examiner time for reviewing  
the computer search results. Therefore, the limited resources

Art Unit: 1636

of the Office no longer permit examination of more than one sequence in an application.

The inventions are distinct, each from the other because of the following reasons:

The products of Groups I-II, VI, VIII-IX, XIV, XVI, and XVIII-XIX are chemically, biologically, and functionally distinct from each other and thus one does not render the others obvious. The product of each group is not needed to produce the products of the other groups (each of which can be isolated from cells or organisms, made synthetically, and/or are self-replicating without the need for the specific products of the other groups). Therefore, the inventions of the groups are capable of supporting separate patents.

Inventions of Groups III-V, VII, X-XIII, XV, and XVII are biologically and functionally different and distinct from each other and thus one does not render the other obvious. The methods of Groups III-V, VII, X-XIII, XV, and XVII comprise steps which are not required for or present in the methods of the other groups. The end result of the methods are different from each other. Thus, the operation, function and effects of these different methods are different and distinct from each

Art Unit: 1636

other. Therefore, the inventions of these different, distinct groups are capable of supporting separate patents.

Inventions of Group III and Group I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the product as claimed can be made by a materially different process, such as synthetically.

Inventions of Group II and Group III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process, such as for a probe.

Inventions of Group VII and Group VI are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially

Art Unit: 1636

different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)).

In the instant case the product as claimed can be made by a materially different process, in a phage display library.

Inventions of Group VI and XI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process, such as for protein purification.

Inventions of Group VIII and Group XII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process, such as regulation of gene expression in vitro.



Art Unit: 1636

Inventions of Group IX and Group XIII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process, such as regulation of gene expression in vitro.

Inventions of Group XVI and XVII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process, such as for storing the data for long term storage.

Except for the specific relationships described above, the inventions of Groups I-II, VI, VIII-IX, XIV, XVI, and XVIII-XIX are unrelated to the inventions of Groups III-V, VII, X-XIII, XV, and XVII. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have

Art Unit: 1636

different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different products of Groups I-II, VI, VIII-IX, XIV, XVI, and XVIII-XIX are not used in or made by the methods of Groups III-V, VII, X-XIII, XV, and XVII.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and the search required for each group is not required for the other groups because each group requires a different non-patent literature search due to each group comprising different products and/or method steps, restriction for examination purposes as indicated is proper.

This application contains claims directed to the following patentably distinct species of the claimed invention:

1. disease species

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 20-26 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected

Art Unit: 1636

consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

Art Unit: 1636

named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a**

Art Unit: 1636

**loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

### **Conclusion**

Certain papers related to this application may be submitted to Art Unit 1636 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone number for the Group is 703-872-9306. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily

Art Unit: 1636

from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Any inquiry concerning rejections or objections in this communication or earlier communications from the examiner should be directed to Terry A. McKelvey whose telephone number is (571) 272-0775. The examiner can normally be reached on Monday through Friday, except for Wednesdays, from about 7:30 AM to about 6:00 PM. A phone message left at this number will be

Art Unit: 1636

responded to as soon as possible (i.e., shortly after the examiner returns to his office).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Remy Yucel can be reached at (571) 272-0781.



Terry A. McKelvey, Ph.D.  
Primary Examiner  
Art Unit 1636

June 28, 2004